Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine Challenge in Depression with Bipolar Risk
NCT02451306Unknown
- Sponsor
- RWTH Aachen University
- Start
- Jun 2015
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of quetiapine in major depressive disorder (MDD) and bipolar disorder (BD) (3 arms), sponsored by RWTH Aachen University. Primary endpoints: BOLD signal during a combined inhibition-reward-task at Day 0, Functional connectivity in the default mode network during resting state at Day 0 and 3 more. Status: unknown.
02
Drugs
quetiapine
03
Conditions
major depressive disorder (MDD)bipolar disorder (BD)
Beyond the preview
Go deeper on NCT02451306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02451306.